The landscape of medical weight management has been revolutionized by GLP-1 receptor agonists like Wegovy and Mounjaro. However, the next frontier in obesity medicine is already on the horizon, promising greater efficacy, more convenience, and entirely new mechanisms of action.
If you are currently managing your weight or considering clinical treatment, here is a glimpse into the breakthrough molecules expected to shape the near future.
High-Dose Oral Semaglutide
Currently, Rybelsus is the only oral GLP-1 receptor agonist available, primarily prescribed for type 2 diabetes at lower doses (up to 14mg). However, clinical trials for a high-dose oral semaglutide (50mg) specifically targeted at obesity have shown remarkable results.
In the OASIS 1 trial, participants taking 50mg of oral semaglutide daily achieved a staggering 15.1% body weight loss over 68 weeks. This matches the efficacy of injectable Wegovy but in a convenient, once-daily pill. This formulation is currently navigating regulatory approval and is highly anticipated by patients who prefer to avoid injections.
Orforglipron: The First Non-Peptide Oral GLP-1
Developed by Eli Lilly, Orforglipron is a novel, non-peptide GLP-1 receptor agonist. Unlike oral semaglutide, which requires strict fasting and a specific water intake to be absorbed in the stomach, Orforglipron is designed to be easily absorbed regardless of food intake.
Phase 2 trial results demonstrated up to 14.7% weight loss after 36 weeks. Because it is a small molecule rather than a complex peptide, it is significantly cheaper and easier to manufacture at scale. This could drastically lower the cost of premium weight loss treatments and alleviate the global supply shortages currently plaguing the market.
Retatrutide: The “Triple G” Agonist
While Wegovy targets one receptor (GLP-1) and Mounjaro targets two (GLP-1 and GIP), Retatrutide targets three: GLP-1, GIP, and Glucagon.
By activating the glucagon receptor in addition to the others, Retatrutide increases the body’s baseline energy expenditure. Phase 2 trial results were unprecedented: participants lost an average of 24.2% of their body weight in just 48 weeks, making it the most potent pharmacological weight loss treatment ever tested. It also showed remarkable efficacy in resolving non-alcoholic fatty liver disease (NAFLD).
MariTide (Maridebart Cafraglutide)
Amgen’s MariTide takes an entirely different approach. It is a bispecific molecule that activates the GLP-1 receptor while blocking the GIP receptor.
What makes MariTide truly revolutionary is its duration of action. Early trials suggest it may only need to be injected once a month, rather than weekly. Furthermore, participants who stopped taking MariTide maintained their weight loss much longer than those who stopped taking Wegovy or Mounjaro, suggesting it might create lasting metabolic changes.
What This Means for Patients
The forthcoming generation of weight loss medications will offer unparalleled choice. Whether you prioritize the convenience of a daily pill without fasting restrictions (Orforglipron), maximum weight loss potential (Retatrutide), or infrequent dosing (MariTide), the clinical toolkit is expanding rapidly.
At Prescriptly, our clinical team continuously monitors these developments to ensure our patients have access to the safest, most effective, and most convenient treatments as soon as they become legally available and approved by the MHRA.